Neuroblastoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• MYCN 0
• AKT 0
• TP53 0
• ALK 3
• B7-H3 7
• ERK 0
• PI3K 0
• MAPK 1
• SNCA 0
• mTOR 0
• NRF2 0
• NRAS 0
• AMPK 0
• BCL-2 0
• EZH2 0
• JNK 0
• KRAS 0
• MYC 0
• PPAR 0
• STAT3 0
• STING 1
• CDK4/6 0
• NTRK 0
• SIRT1 0
• CD19 3
• PARP 2
• RAS 1
• TDP-43 0
• VEGF 1
• BDNF 0
• HDAC 0
• HMGB1 0
• ROS1 1
• YAP 0
• BRAF 0
• FAK 0
• HIF-1 0
• IL-1 0
• IL-15 3
• MEK 0
• NLRP3 0
• PINK1 0
• PTEN 0
• APP 0
• BACE1 0
• CD47 0
• CGRP 0
• EGFR 1
• FGFR 0
• GPX4 0
• IDH 1
• IL-6 0
• MAPT 0
• MDM2 0
• PD-1 0
• PD-L1 0
• RET 0
• SOD1 0
• TFEB 0
• TNF 0

24 of 32+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

No running funded project names this disease yet.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

  NCT02650401· Hoffmann-La Roche· Source

• DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

  NCT05770037· Cancer Research UK· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 15
• Organoids 2
• Mendelian Randomization Analysis 5
• CRISPR-Cas Systems 5
• Gene Expression Profiling 45
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 4
• Proteomics 20
• Metabolomics 12
• Mass Spectrometry 10
• Flow Cytometry 19
• Immunohistochemistry 20
• Liquid Biopsy 3
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 65
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 21
• Machine Learning 11
• Deep Learning 4
• Cohort Studies 8
• Genome-Wide Association Study 5

• Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

  Clin Cancer Res, Sept 2026

• Detection of KRAS, NRAS and BRAF Mutations in Liquid Biopsy from Patients with Colorectal Cancer.

  Oncol Res, Jan 2026

• Copy-Number Aberrations in Circulating Tumor DNA Enable Diagnosis and Risk Stratification of Pediatric Neuroblastic Tumors.

  Cancer Res Commun, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.